|
Market Closed -
London S.E.
11:35:13 2026-09-24 EDT
|
5-day change | 1st Jan Change | ||
| 88.50 GBX | 0.00% |
|
+2.91% | +9.94% |
| 08-13 | EARNINGS AND TRADING: tinybuild sues Max Ent; Light Science loss grows | AN |
| 08-13 | Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed Journal | CI |
Company Valuation: Arecor Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 111.3 | 73.48 | 55.89 | 27.75 | 30.39 | 33.41 | - |
| Change | - | -34% | -23.94% | -50.35% | 9.52% | 9.94% | - |
| Enterprise Value (EV) 1 | 93.02 | 60.68 | 49.14 | 24.49 | 24.36 | 32.09 | 36.62 |
| Change | - | -34.77% | -19.01% | -50.16% | -0.54% | 31.74% | 14.09% |
| P/E | -14.8x | -7.5x | -6.52x | -2.37x | - | - | - |
| PBR | - | 4.21x | 5.87x | 4.21x | 4.92x | 57.5x | - |
| PEG | - | -0.4x | 0.5x | -0.2x | - | - | - |
| Capitalization / Revenue | 96.1x | 30.6x | 12.2x | 5.49x | 9.61x | 38x | 31.8x |
| EV / Revenue | 80.3x | 25.3x | 10.7x | 4.85x | 7.7x | 36.5x | 34.9x |
| EV / EBITDA | -14.8x | -5.9x | -5.66x | -3.52x | -6.95x | -5.6x | -8.78x |
| EV / EBIT | -14.4x | -5.71x | -5.36x | -3.31x | 36.5x | -5.18x | -8.18x |
| EV / FCF | - | -5.48x | -8.2x | -2.67x | -9.9x | -6.89x | -30.6x |
| FCF Yield | - | -18.3% | -12.2% | -37.5% | -10.1% | -14.5% | -3.27% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.27 | -0.32 | -0.28 | -0.31 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.158 | 2.403 | 4.573 | 5.053 | 3.163 | 0.8785 | 1.05 |
| EBITDA 1 | -6.268 | -10.29 | -8.679 | -6.963 | -3.506 | -5.729 | -4.172 |
| EBIT 1 | -6.439 | -10.63 | -9.175 | -7.409 | 0.667 | -6.2 | -4.474 |
| Net income | -6.169 | -9.26 | -8.554 | -10.24 | - | - | - |
| Net Debt 1 | -18.32 | -12.81 | -6.752 | -3.257 | -6.032 | -1.32 | 3.203 |
| Reference price 2 | 4.0000 | 2.4000 | 1.8250 | 0.7350 | 0.8050 | 0.8850 | 0.8850 |
| Nbr of stocks (in thousands) | 27,835 | 30,618 | 30,627 | 37,757 | 37,757 | 37,757 | - |
| Announcement Date | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 36.53x | -5.6x | -.--% | 44.3M | |
| 32.83x | 5.9x | 17.66x | 0.99% | 47.56B | |
| 34.5x | 3.33x | 14.35x | -.--% | 44.09B | |
| 47.81x | 5.54x | 30.34x | -.--% | 41.5B | |
| -19.6x | 208.56x | -21.12x | -.--% | 40.88B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.67B | |
| 35.1x | 5.76x | 26.17x | -.--% | 17.23B | |
| 25.39x | 2.19x | 9.48x | 1.05% | 15.06B | |
| -55x | 9.03x | 220.54x | -.--% | 13.82B | |
| Average | 15.98x | 31.62x | 34.64x | 0.27% | 27.76B | |
| Weighted average by Cap. | 21.17x | 38.71x | 24.42x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AREC Stock
- Valuation Arecor Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
